Upload
simul8-corporation
View
106
Download
0
Embed Size (px)
Citation preview
OCCUSIMSupporting eye care in a complex world
Pathway Communications Ltd
Eren Demir David Southern
Director
Pathway Communications Ltd
Associate Professor Hertfordshire University
Director
Pathway Communications Ltd
What OCCUSIM does
OCCUSIM models intravitreal pathway using computer software enabling the trust to see what will happen if they invest in new ways of doing things
Increase the number of patients treated
Help more patients get the treatment they desperately need
What OCCUSIM does
Forecast•Forecast hospital activity using a combination of hospital patient level data
Simulation
•The forecasts are entered into the simulation, which along with other key information about the service, creates a simulation of resources required for the next twelve months
Report
•Each quarter the process is updated so that Trusts always have a 12 month view ahead.
•Each quarter Trusts also receive an alternative scenario such as the impact of introduction of a new pathway or a new device
Forecasting – making sure your trust is
always aware of the challenges ahead
OCCUSIM takes the last 36 months of data
Using specialist software OCCUSIM splits the Trust data and HES data by age and forecasts each age groups individually
The forecasts are then imported into the Trust’s intravitreal service simulation
Simulation goes beyond forecasting
OCCUSIM takes key information about the Trust’s intravitreal service and creates a virtual copy of the service
It uses the Trust’s data to simulate the next twelve months activity one patient at a time
The information is collated each quarterly to provide the Trust’s unique report
Simulation – Scenario planning
What happens if…• If you change to treat and
extend pathway?• You adopt a new surgical
method?• You invest in a new device?
Each quarter OCCUSIM will run one of these or similar scenarios for the Trust.
The Trust can also run additional scenarios at any time.
Trusts can constantly improve their service by testing and
implementing changes that will enable them to treat more patients
Use OCCUSIM - Virtual clinicsExample based on real data - Hospital A• Hospital A has around 40,000 attendances a year
of which 10,000 use intravitreal services• According to Hospital A’s data they have 3,474
‘non discharged’ patients who have been in the service for the last 24 months
• Of these 3,474 patients 970 patients have not been treated for the last two years but have been followed up in the last six months
• We tested the virtual service by removing the 970 patients from the system and then increasing the number of new patients by 25%
Data flow chart: patients
INTRAVITREAL SERVICES(6,520 patient’s)
AMD(1,124)
DR(2,752)
LucentOP injections
(518)
Observations(606)
LucentOP (injections)
(99)
FU assessment(99)
Observations(2,459)
4%
Laser (194)
46%
FU assessment(518)
54%
FU assessment(155)
7%89%
MR(2,644)
LucentOP (injections)
(152)
FU assessment(152)
Observations(2,439)
5.7%
Laser (53)
FU assessment(53)
2.1%92.2%
42.3%
Y1(4)
Y2(3)
Y3(2.5)
Y1(4.8)
Y2(4)
Y3(3.6)
Y1(1.7)
Y2(1.6)
Y3(1.4)
17.2% 40.5%
Y1(3.5)
Y2(2.6)
Y3(2.6)
Y1(3.3)
Y2(3.1)
Y3(3.6)
Y1(1.6)
Y2(NA)
Y3(NA)
Y1(2.1)
Y2(2.3)
Y3(2)
Y1(1.4)
Y2(1.4)
Y3(1.2)
Y1(4)
Y2(2.8)
Y3(2.4)
Y1(3.7)
Y2(3.1)
Y3(2.5)
Y1(1.2)
Y2(NA)
Y3(NA)
Y1(2.8)
Y2(1.9)
Y3(1.3)
Y1(1.4)
Y2(1.4)
Y3(1.1)
Date range03/04/2013 – 31/03/2016
The Simulation
OCCUSIM - Virtual clinics
Monthly averagesCurrent Service
Virtual Clinic + 0% increase in new referrals
Virtual Clinic + 25% increase in new referrals
% increase
New attendances 113 113 141 25%Follow-ups 735 660 777 6%Consultant utilisation 74% 67% 78% 5%Nurse utilisation 60% 54% 68% 13%Consultation room utilisation 52% 47% 55% 6%Injection bed utilisation 30% 29% 33% 10%Number of Lucentis injections 172 171 187 9%Costing £159,962.77 £153,361.36 £186,895.79 17%Revenue £219,503.33 £209,720.93 £258,701.55 18%Surplus £59,540.56 £56,359.25 £71,805.76 21%
Increase in surplus £144,000 per year
Virtual clinic + treat and extend
Monthly averages Current ServiceVirtual Clinic + 0% increase in new attendances
Virtual Clinic + 25% increase in new attendances
% change
New attendances 119 119 147 23%Follow-ups 745 655 707 -5%Consultant utilisation 73% 65% 71% -2%Nurse utilisation 72% 65% 71% -2%Clinic room utilisation 54% 49% 53% -2%Injection bed utilisation 30% 30% 32% 8%Number of Lucentis injections 169 169 182 8%Costing £154,538.27 £156,761.27 £170,112.67 10%Revenue £211,345.74 £211,345.74 £231,487.73 10%Surplus £56,807.47 £54,584.47 £61,375.05 8%
2 x Nurse injectors + increase in DMO demand
Monthly averages Current ServiceTwo Nurse Injectors + no other change
Two nurse injectors + 5% increase in DMO arrivals/month
Two nurse injectors + 5% increase in DMO arrivals/month + 35% increase in use of Ozurdex for RVO and DMO (reduction in Lucentis and Eylea accordingly)
% change
New attendances 94 94 109 111 18%Follow-ups 1088 1092 1196 1132 4%Consultant utilisation 98% 78% 97% 90% -8%Nurse utilisation 59% 58% 68% 62% 5%Clinic room utilisation 75% 74% 79% 75% 0%Injection bed utilisation 45% 46% 52% 45% 0%Number of Lucentis injections 330 330 387 324 -2%Number of Eylea injections 272 272 306 280 3%Number of Ozurdex injections 9 9 11 45 400%Costing £517,028.72 £522,028.72 £599,864.00 £551,232.39 7%Revenue £639,549.50 £639,549.50 £736,363.07 £677,951.75 6%Surplus £122,520.78 £117,520.78 £136,499.07 £126,719.36 3%
Pathway Communications
Specialists in healthcare analytics and
patient pathway simulations
OCCUSIMSupporting eye care in a complex worldenquiries@pathwaycommunications.co.ukwww.pathwaycommunications.co.uk
Thank you for joining us
The webinar recording is available on SIMUL8Healthcare.com
Continue the discussion:
SIMUL8 in Health